On Monday I hit the eight-week mark on Tremfya (guselkumab), Janssen’s new biologic indicated for plaque psoriasis. Over the weekend, it felt like the remaining psoriasis started melting away as lesions flattened, looked less red, and even disappeared. But with a change in medical providers I'm still unsure if insurance will continue to cover the cost of Tremfya.
Last week I finally conjured up the courage to call my insurance provider about the Otezla denial. Right away I knew why I procrastinated.
Today I found out that insurance denied my dermatologist’s prescription for Otezla (apremilast). With so many days passing before hearing I assumed the scrip ran into issues. I was right.